-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-523141-10-00
4
2026-03-20
Active Psoriatic Arthritis
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-523075-32-00
5
2026-03-09
chronic kidney disease
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-522703-14-00
5
2026-02-17
"Moderate to severe obstructive sleep apnea (OSA) in adults living wit
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521802-17-00
5
2026-01-30
Erosive/inflammatory osteoarthritis of the hands
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2025-522631-34-00
5
2026-01-14
Osteoarthritis
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-519745-30-01
9
2025-12-19
Immune Thrombocytopenia (ITP)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-519960-42-00
4
2025-12-11
PIK3CA-Related Overgrowth Spectrum (PROS)
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2024-515125-28-00
4
2025-12-08
Non-obstructive hypertrophic cardiomyopathy
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2023-508874-27-00
5
2025-12-02
Heart condition
-
2024-520206-19-00
5
2025-12-02
Hyperuricemia associated with gout.